Back to mobile site

Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC)

November 15, 2024 7:44 AM EST Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $30.00 price target on Benitec BioPharma (NASDAQ: BNTC).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login